文献速递主动脉疾病

编辑精选——现成外分支与内分支覆膜支架治疗胸腹主动脉瘤的B.R.I.O.研究组结局比较

Editor's Choice - Outcomes of Off the Shelf Outer Branched Versus Inner Branched Endografts in the Treatment of Thoraco-Abdominal Aortic Aneurysm in the B.R.I.O. (BRanched Inner - Outer) Study Group.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2024-04-16

这项多中心回顾性研究(2020—2023年)比较了现成内分支E-nside与外分支t-Branch覆膜支架行分支腔内修复胸腹主动脉瘤的结局。共纳入163例患者(E-nside组79例、t-Branch组84例),两组30天技术成功率和主要不良事件无显著差异,一年靶血管与主体支架稳定性无显著差异;E-nside可能所需胸主动脉覆盖更短、肾动脉桥接长度更短,但未导致临床结局的显著差异。

要点

  • 两组30天死亡率分别为1%与2%(p=.62),任何主要不良事件分别为18%与21%(p=.55)。
  • 一年免于靶血管不稳定分别为96±3%与95±3%(p=.58),免于主体支架不稳定分别为98±2%与97±3%(p=.46)。
  • E-nside组肾动脉桥接长度更短(66±17 mm vs 76±20 mm;p<.010),但临床结局无显著差异。

核心结论

  • 两种现成支架均提供了良好的早期和一年结果。
  • E-nside可能所需胸主动脉覆盖更短、肾动脉桥接长度更短,且同期近端胸主动脉或远端腹主动脉分叉支架植入更少,但这些方面未导致临床结局的显著差异。

研究设计与样本

  • 多中心回顾性研究(2020—2023年),纳入163例使用内分支E-nside(79例,307根靶血管)或外分支t-Branch(84例,325根靶血管)行分支腔内修复的胸腹主动脉瘤患者。

主要发现

  • 动脉瘤范围I—III在91例(55.8%;E-nside组47%、t-Branch组66%),IV在72例(44.2%;E-nside组53%、t-Branch组34%)(p=.011)。
  • 使用辅助近端胸主动脉覆膜支架在E-nside组为43% vs t-Branch组69%(p<.001);在IV型胸腹主动脉瘤中,E-nside组胸主动脉支架使用更少(14% vs 76%;p<.001)且覆盖长度更短(p=.024)。
  • E-nside组肾动脉桥接长度更短(66±17 mm vs 76±20 mm;p<.010),远端分叉覆膜支架使用更少(53% vs 80%;p<.001)。
  • 30天结果:E-nside组与t-Branch组死亡率分别为1% vs 2%(p=.62),任何主要不良事件分别为18% vs 21%(p=.55),卒中率分别为3% vs 0%(p=.23),择期脊髓缺血率分别为5% vs 8%(p=.40)。
  • 一年时,E-nside组与t-Branch组免于靶血管不稳定分别为96±3% vs 95±3%(p=.58),免于主体支架不稳定分别为98±2% vs 97±3%(p=.46)。

关键数值与推荐

  • 30天技术成功率和主要不良事件为终点指标,但原文未报告具体技术成功率数值。
  • 一年免于靶血管不稳定和主体支架不稳定为终点指标,数值如上。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to compare two commercially available off the shelf branched endografts for thoraco-abdominal aortic aneurysm (TAAA) repair, namely the E-nside (Artivion) and Zenith t-Branch (Cook Medical) devices. METHODS: This multicentre retrospective study (2020 - 2023) included patients treated by branched endovascular aortic repair (BEVAR) for TAAA using the inner branched E-nside or the outer branched t-Branch. Endpoints were 30 day technical success and major adverse events (MAEs) as well as one year freedom from target vessel instability and main endograft instability. RESULTS: The study included 163 patients: 79 (307 target vessels) treated with E-nside and 84 (325 target vessels) with t-branch. Aneurysm extent was I - III in 91 patients (55.8%; 47% of E-nside and 66% of t-Branch) and IV in 72 patients (44.2%; 53% of E-nside and 34% of t-Branch) (p = .011). An adjunctive proximal thoracic endograft was used in 43% of E-nside vs. 69% of t-Branch (p < .001), with less frequent thoracic endografting (14% vs. 76%; p < .001) and shorter length of coverage (p = .024) in extent IV TAAA treated by E-nside. E-nside cases had shorter renal artery bridging lengths (66 ± 17 mm vs. 76 ± 20 mm; p < .010) and less frequent use of a distal bifurcated endograft (53% vs. 80%; p < .001). Comparing 30 day results, the mortality rate was 1% vs. 2% (p = .62), any MAE occurred in 18% vs. 21% (p = .55), the stroke rate was 3% vs. 0% (p = .23), and the elective spinal cord ischaemia rate was 5% vs. 8% (p = .40) for E-nside and t-Branch, respectively. At one year, freedom from target vessel instability was 96 ± 3% for E-nside and 95 ± 3% for t-Branch (p = .58), and freedom from endograft instability was 98 ± 2% vs. 97 ± 3% (p = .46), respectively. CONCLUSION: Both off the shelf devices provided excellent early and one year results. The E-nside may require shorter thoracic aortic coverage and bridging length for the renal arteries, and less frequent implantation of a concomitant proximal thoracic or distal abdominal bifurcated endograft. However, these aspects did not determine significant differences in clinical outcomes.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Piazza M, Squizzato F, Pratesi G, et al. Editor's Choice - Outcomes of Off the Shelf Outer Branched Versus Inner Branched Endografts in the Treatment of Thoraco-Abdominal Aortic Aneurysm in the B.R.I.O. (BRanched Inner - Outer) Study Group. Eur J Vasc Endovasc Surg. 2024. PMID: 38636923. doi:10.1016/j.ejvs.2024.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。